Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 94

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 94
---
without any further action or passage of time. In addition, the 2022 Letter Agreement amended the CIC Severance Agreement (as defined below) to provide the CIC Performance Option Termination Treatment, as described below. (3) In the event that Mr. Ingram experiences a termination of employment not in connection with a CIC, the stated dollar amount in this row reflects the spread value of the unvested portion of all remaining tranches of the Performance Option, as described below, to be achieved, assuming a stock price of $121.59 per share, the closing price of our common stock on the Nasdaq Global Select Market on December 31, 2024, the last trading day of our 2024 fiscal year. In the event that Mr. Ingram experiences a termination of employment in connection with a CIC, the stated dollar amount in this row reflects the spread value of the unvested portion of the next tranche of the Performance Option, as described below, to be achieved, assuming a stock price of $121.59 per share, the closing price of our common stock on the Nasdaq Global Select Market on December 31, 2024, the last trading day of our 2024 fiscal year. (4) For more information related to a qualified termination of employment not in connection with a change in control, please see “ Compensation Agreements for Named Executive Officers – Douglas S. Ingram – President and Chief Executive Officer”. Other Named Executive Officers The table below reflects the amount of compensation payable to each of our named executive officers, other than our President and Chief Executive Officer, in the event of a termination of the executive’s employment by us without “cause” or due to a “constructive termination” (each such term, as defined in the Severance Agreements described below) (i) upon or within 12 months following a change in control, and (ii) not in connection with, or within 12 months following, a change in control. The table below reflects the agreements with our named executive officers (other than our President and Chief Executive Officer) in place as of December 31, 2024. Mr. Brown did not receive any severance or other benefits in connection with his resignation of employment, other than payment of his 2024 annual bonus ($387,725) based on actual performance in 2024 on the same basis as other executive officers, and continued vesting of his outstanding equity awards pursuant to their existing terms through his last day of employment on March 24